Human Metabolome Technologies, Inc. (JP:6090)
:6090
Want to see JP:6090 full AI Analyst Report?
Top Page
Human Metabolome Technologies, Inc.
(6090)
Select Model
Select Model
Rating:67Neutral
Price Target:
¥695.00
▼(-2.80% Downside)
Action:Reiterated
Date:10/22/25
The stock is supported by strong financial performance, particularly in profitability and balance sheet strength. However, technical indicators suggest bearish momentum, and valuation is moderate. The lack of revenue growth is a concern.
Positive Factors
Proprietary metabolomics technology
Human Metabolome Technologies' proprietary metabolomics platforms underpin a durable competitive advantage by creating specialized capabilities and validated workflows. This supports long-term service relationships with pharma, biotech, food and academic customers and raises switching costs for clients.
Negative Factors
Negative revenue trend
Sustained or recurring top-line decline undermines scalability: with falling revenue, even strong margins yield less absolute profit and cash. Continued negative growth constrains the firm’s ability to leverage fixed costs and to justify incremental investments in capacity or sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary metabolomics technology
Human Metabolome Technologies' proprietary metabolomics platforms underpin a durable competitive advantage by creating specialized capabilities and validated workflows. This supports long-term service relationships with pharma, biotech, food and academic customers and raises switching costs for clients.
Read all positive factors
Human Metabolome Technologies, Inc. (6090) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.71B
Dividend Yield2.35%
Average Volume (3M)10.25K
Price to Earnings (P/E)7.8
Beta (1Y)0.24
Revenue Growth-13.41%
EPS Growth-60.43%
CountryJP
Employees58
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)43.61
Shares Outstanding5,919,797
10 Day Avg. Volume8,100
30 Day Avg. Volume10,250
Financial Highlights & Ratios
PEG Ratio2.95
Price to Book (P/B)2.36
Price to Sales (P/S)3.09
P/FCF Ratio19.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Human Metabolome Technologies, Inc. Business Overview & Revenue Model
Company Description
Human Metabolome Technologies, Inc. (6090) is a biotechnology company specializing in the analysis of human metabolites to advance the understanding of human health and disease. The company operates primarily in the life sciences sector, offering ...
How the Company Makes Money
null...
Human Metabolome Technologies, Inc. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
85
Very Positive
Cash Flow
72
Positive
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.46B | 1.35B | 1.30B | 1.22B | 1.12B |
| Gross Profit | 922.00M | 869.33M | 859.75M | 840.00M | 806.02M |
| EBITDA | 353.00M | 350.31M | 319.65M | 329.02M | 108.33M |
| Net Income | 256.00M | 243.25M | 285.76M | 267.79M | 58.21M |
Balance Sheet | |||||
| Total Assets | 2.37B | 2.60B | 2.29B | 2.07B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.79B | 1.66B | 1.50B | 1.25B |
| Total Debt | 110.47M | 226.30M | 226.52M | 233.19M | 152.70M |
| Total Liabilities | 466.13M | 656.84M | 518.91M | 583.39M | 363.28M |
| Stockholders Equity | 1.91B | 1.95B | 1.77B | 1.49B | 1.26B |
Cash Flow | |||||
| Free Cash Flow | 225.00M | 202.70M | 168.11M | 177.92M | -62.04M |
| Operating Cash Flow | 373.00M | 236.79M | 284.96M | 324.03M | -34.17M |
| Investing Cash Flow | -197.00M | -32.44M | -116.75M | -152.31M | -25.99M |
| Financing Cash Flow | -369.00M | -73.15M | -13.75M | 80.49M | 86.22M |
Human Metabolome Technologies, Inc. Technical Analysis
Negative
715.00
Price Trends
706.94
Negative
688.12
Positive
712.95
Negative
Market Momentum
-0.61
Negative
48.41
Neutral
37.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6090, the sentiment is Negative. The current price of 715 is above the 20-day moving average (MA) of 701.95, above the 50-day MA of 706.94, and above the 200-day MA of 712.95, indicating a bearish trend. The MACD of -0.61 indicates Negative momentum. The RSI at 48.41 is Neutral, neither overbought nor oversold. The STOCH value of 37.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6090.
Human Metabolome Technologies, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥7.18B | 8.02 | ― | 4.57% | 8.02% | 43.89% | |
70 Outperform | ¥9.30B | 21.31 | ― | 2.53% | 3.28% | -30.16% | |
67 Neutral | ¥3.71B | 7.80 | ― | 2.35% | -13.41% | -60.43% | |
63 Neutral | ¥131.82B | 19.87 | 5.94% | 3.34% | 4.94% | 26.92% | |
53 Neutral | ¥50.79B | 12.89 | ― | 2.79% | 0.34% | -7.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥3.06B | -4.91 | ― | ― | 12.57% | 22.66% |
* Healthcare Sector Average
JP:6090
Human Metabolome Technologies, Inc.
626.00
-75.87
-10.81%
JP:4694
BML
3,525.00
707.71
25.12%
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,220.00
-51.22
-4.03%
JP:3386
Cosmo Bio Co., Ltd.
1,240.00
133.86
12.10%
JP:4556
Kainos Laboratories, Inc.
2,273.00
1,040.00
84.35%
JP:4882
Perseus Proteomics, Inc.
180.00
-266.00
-59.64%
Human Metabolome Technologies, Inc. Corporate Events
Human Metabolome Technologies Posts Profit Decline but Maintains Strong Capital Base
May 13, 2026
Human Metabolome Technologies, Inc., listed on the Tokyo Standard market, operates in the life-science analytics and metabolomics sector, supplying analytical technologies and services to pharmaceutical, biotech, and research institutions. Its off...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.